

International clinical harmonization of glycated hemoglobin in Japan: From Japan Diabetes Society to National Glycohemoglobin Standardization Program values

Atsunori Kashiwagi · Masato Kasuga · Eiichi Araki · Yoshitomo Oka · Toshiaki Hanafusa · Hiroshi Ito · Makoto Tominaga · Shinichi Oikawa · Mitsuhiko Noda · Takahiko Kawamura · Tokio Sanke · Mitsuyoshi Namba · Mitsuru Hashiramoto · Takayuki Sasahara · Yoshihiko Nishio · Katsuhiko Kuwa · Kohjiro Ueki · Izumi Takei · Masao Umemoto · Masami Murakami · Minoru Yamakado · Yutaka Yatomi · Hatsumi Ohashi · Committee on the Standardization of Diabetes Mellitus-Related Laboratory Testing of Japan Diabetes Society (JDS)

Published online: 13 March 2012
© The Japan Diabetes Society 2012

In 1999, the Japan Diabetes Society (JDS) launched the previous version of the diagnostic criteria of diabetes mellitus, in which JDS took initiative in adopting glycated haemoglobin (HbA1c) as an adjunct to the diagnosis of diabetes. In contrast, in 2009 the International Expert Committee composed of the members of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD) manifested the recommendation regarding the use of HbA1c in diagnosing diabetes mellitus as an alternative to glucose measurements

based on the update evidences indicating that HbA1c has several advantages as a marker of chronic hyperglycemia [1–3]. The JDS extensively evaluated the usefulness and feasibility of more extended use of HbA1c in the diagnosis of diabetes based on Japanese epidemiological data, and then the “Report of the Committee on the Classification and Diagnostic Criteria of Diabetes Mellitus” was published in the *Diabetology International* [4] and *Journal of Diabetes Investigation* [5]. The new diagnostic criterion in Japan came into effect on July 1, 2010. According to the

A. Kashiwagi (✉)
Shiga University of Medical Science Hospital, Shiga, Japan
e-mail: kashiwagi@belle.shiga-med.ac.jp

M. Kasuga
Research Institute, National Center for Global Health and Medicine, Tokyo, Japan

E. Araki
Department of Metabolic Medicine, Faculty of Life Sciences, Kumamoto University, Kumamoto, Japan

Y. Oka
Department of Metabolic Diseases, Center for Metabolic Diseases, Tohoku University Graduate School of Medicine, Sendai, Japan

T. Hanafusa
Department of Internal Medicine (I), Osaka Medical College, Osaka, Japan

H. Ito
Okhotsk-kai Hospital, Kitami, Hokkaido, Japan

M. Tominaga
Rehabilitation Hananoie Hospital, Tochigi, Japan

S. Oikawa
Division of Endocrinology and Metabolism, Department of Internal Medicine, Nippon Medical School, Tokyo, Japan

M. Noda
Department of Diabetes and Metabolic Medicine, Diabetes Research Center, National Center for Global Health and Medicine, Tokyo, Japan

T. Kawamura
Division of Diabetes and Endocrine, Department of Internal Medicine, Chubu Rosai Hospital, Aichi, Japan

T. Sanke
Department of Clinical Laboratory Medicine, Wakayama Medical University, Wakayama, Japan

M. Namba
Division of Diabetes and Metabolism, Department of Internal Medicine, Hyogo College of Medicine, Hyogo, Japan

M. Hashiramoto
Division of Diabetes, Metabolism, and Endocrinology, Kawasaki Medical School, Okayama, Japan

new version of the criteria, HbA1c (JDS) $\geq 6.1\%$ is now considered to indicate a diabetic type, but the previous diagnosis criteria of high plasma glucose (PG) levels to diagnose diabetes mellitus also need to be confirmed. Those are as follows: (1) FPG ≥ 126 mg/dL (7.0 mmol/L), (2) 2-h PG ≥ 200 mg/dL (11.1 mmol/L) during an OGTT, or (3) casual PG ≥ 200 mg/dL (11.1 mmol/L). If both PG criteria and HbA1c in patients have met the diabetic type, those patients are immediately diagnosed to have diabetes mellitus [4, 5].

In the report, the HbA1c measurements in Japan are well calibrated with Japanese-Clinical-Laboratory-Use Certified Reference Material (JCCRM). The certified values are determined by a high resolution type ion-exchange High Performance Liquid Chromatography (HPLC) (KO 500 method) and certified using the designated comparison method (DCM) of the Japan Society of Clinical Chemistry (JSCC) and the JDS. After incorporating a proportional bias correction to the value anchored to the peptide mapping method of the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC), the DCM actually measures β -N-mono-deoxyfructosyl hemoglobin and has an intercept approximately equal to zero against the peptide mapping method of IFCC in measuring fresh raw human blood samples. Furthermore, standardization of HbA1c in Japan was initiated in 1993, and the serial reference materials from JDS Lot 1 to JDS Lot 4 are well certified using the DCM until now. In the new diagnosis criteria [4, 5], the new cut-off point of HbA1c (JDS) for diagnosis of diabetes mellitus is 6.1%, which is equivalent to the internationally used HbA1c

(NGSP) 6.5%, as HbA1c (NGSP) (%) is reported to be equivalent to $1.019 \times \text{HbA1c (JDS)\%} + 0.3\%$, which is reasonably estimated by the equation of HbA1c (JDS)% + 0.4%, as the difference between the two equations is within error of HbA1c measurements (2–3%).

However, on October 1, 2011, the Reference Material Institute for Clinical Chemistry Standards (ReCCS, Kanagawa, Japan) was certified as an Asian Secondary Reference Laboratory (ASRL) using the KO 500 method and the reference materials JCCRM411-2 (JDS Lot 4) after successful completion of NGSP network laboratory certification. Therefore, the HbA1c unit is now traceable to the Diabetes Control and Complications Trial (DCCT) reference method. The comparison was performed with the Central Primary Reference Laboratory (CPRL) in the University of Missouri School of Medicine. Conversion equation from HbA1c (JDS) to HbA1c (NGSP) units is officially certified as follows: NGSP (%) = $1.02 \times \text{JDS (\%)} + 0.25\%$, conversely, JDS (%) = $0.980 \times \text{NGSP (\%)} - 0.245\%$. Based on this equation, in the range of JDS values $\leq 4.9\%$, NGSP (%) = JDS (%) + 0.3%, in the range of JDS 5.0–9.9%, NGSP (%) = JDS (%) + 0.4%, and in the range of JDS 10–14.9%, NGSP (%) = JDS (%) + 0.5%. These results show that the previous equation of NGSP (%) = JDS (%) + 0.4% is also confirmed in the present equation considering a 2–3% error of HbA1c measurements. The council meeting of the JDS finally decided to use HbA1c (NGSP) values in clinical practice from April 1, 2012, although HbA1c (JDS) values will be included until people become familiar with the new expression. Finally, it is also important

T. Sasahara
Department of Metabolic Medicine, Kumamoto Regional Medical Center, Kumamoto, Japan

Y. Nishio
Department of Diabetes and Endocrine Medicine, Kagoshima University Graduate School of Medical and Dental Science, Kagoshima, Japan

K. Kuwa
Bio-Medical Standards Section, Organic Analytical Chemistry Division, National Metrology Institute of Japan, National Institute of Advanced Industrial Science and Technology, Tsukuba, Ibaraki, Japan

K. Ueki
Department of Diabetes and Metabolic Diseases, Graduate School of Medicine, University of Tokyo, Tokyo, Japan

I. Takei
Department of Internal Medicine, Center for Diabetes and Endocrinology, Ichikawa General Hospital, Tokyo Dental College, Chiba, Japan

M. Umemoto
Reference Material Institute for Clinical Chemistry Standards, Kanagawa, Japan

M. Murakami
Department of Clinical Laboratory Medicine, Gunma University Graduate School of Medicine, Maebashi, Gunma, Japan

M. Yamakado
Center for Multiphasic Health Testing and Services, Mitsui Memorial Hospital, Tokyo, Japan

Y. Yatomi
Department of Clinical Laboratory Medicine, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

H. Ohashi
Division of Clinical Laboratory, Department of Medical Technology, Tokyo Saiseikai Mukoujima Hospital, Tokyo, Japan

Table 1 Differences in HbA1c values between JDS and NGSP for assessments of diagnosis and treatment of diabetes mellitus—Diagnostic reference values of HbA1c (NGSP) and HbA1c (JDS)

Diagnostic reference values	HbA1c(NGSP)	HbA1c(JDS)
Standard range	4.6% ~ 6.2%	4.3% ~ 5.8%
Diabetes range	≥6.5%	≥6.1%
Possible diabetes range	6.0% ~ 6.4%	5.6% ~ 6.0%
High risk range for diabetes	5.6% ~ 5.9%	5.2% ~ 5.5%

Table 2 Differences in HbA1c values between JDS and NGSP for assessments of diagnosis and treatment of diabetes mellitus—Assessments of the glycemic control using HbA1c

Assessment of control state	HbA1c(NGSP)	HbA1c(JDS)
Excellent	<6.2%	<5.8%
Good	6.2% ~ 6.8%	5.8% ~ 6.4%
Fair	Inadequate 6.9% ~ 7.3%	6.5% ~ 6.9%
	Not good 7.4% ~ 8.3%	7.0% ~ 7.9%
Poor	≥8.4%	≥8.0%

to emphasize that the new HbA1c (NGSP) values can be directly measured and printed out from April 1, 2012. However, both new diagnostic reference values and target

values of glycemic control have been adjusted to those equivalent values of HbA1c (JDS) as shown in the Tables 1 and 2.

References

1. International Expert Committee. International expert committee report on the role of the A1C assay in the diagnosis of diabetes. *Diabetes Care*. 2009;32:1327–34.
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. *Diabetes Care*. 2010;33(Suppl):562–9.
3. Report of a World Health Organization Consultation. Use of glycated haemoglobin (HbA1c) in the diagnosis of diabetes mellitus. *Diabetes Res Clin Pract*. 2011;93:299–309.
4. The committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the Committee on the classification and diagnostic criteria of diabetes mellitus. *Diabetol Int*. 2010;1:2–20.
5. The committee of Japan Diabetes Society on the Diagnostic Criteria of Diabetes Mellitus. Report of the committee on the classification and diagnostic criteria of diabetes mellitus. *J Diabetes Invest*. 2010;1:212–28.